Agonist-directed signaling of serotonin 5-HT2c receptors: Differences between serotonin and lysergic acid diethylamide (LSD)

Neuropsychopharmacology

Volumn 21, Issue , 1999, Pages 77S-81S

  Backstrom, Jon R ^a   Chang, Mike S ^a   Chu, Hsin ^a   Niswender, Colleen M ^a   Sanders Bush, Elaine ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A; 5 HT2C; Calcium; Hallucinogen; Phosphoinositide; Phosphorylation; Serotonin

Indexed keywords

CALCIUM; LYSERGIDE; PHOSPHATIDYLINOSITIDE; SEROTONIN; SEROTONIN 2C RECEPTOR;

ARTICLE; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RNA EDITING; SEROTONINERGIC TRANSMISSION; SIGNAL TRANSDUCTION;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MICE; PHOSPHATIDYLINOSITOLS; RATS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; RNA EDITING; SEQUENCE ALIGNMENT; SEROTONIN; SEROTONIN AGONISTS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 0032844031     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00005-6     Document Type: Article

References (25)

1. Backstrom JR, Westphal RS, Canton H, Sanders-Bush E (1995): Identification of rat serotonin 5-HT2C receptors as glycoproteins containing N-Linked oligosaccharides. Mol Brain Res 33:311-318
2. Backstrom JR, Sanders-Bush E (1997): Generation of antipeptide antibodies against serotonin 5-HT2A and 5-HT2C receptors. J Neurosci Methods 77:109-117
3. Barker EL, Westphal RS, Schmidt D, Sanders-Bush E (1994): Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor lignads. J Biol Chem 269:11687-11690
4. Berg KA, Maayani S, Clarke WP (1996): 5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like function via arachadonic acid metabolism. Mol Pharma- col 50:1017-1023
5. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998): Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104
6. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB (1997): Regulation of sero- tonin-2C receptor G-protein coupling by RNA editing. Nature 387:303-308
7. Burris KD, Breeding M, Sanders-Bush E (1991): (+)Lysergic acid diethylamide, but not its nonhallucinogenic conge- ners, is a potent serotonin 5-HT1C receptor agonist. J Pharmacol Exp Ther 258:891-896
8. Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (1998): Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology 136:409-414
9. Gaddum JH (1953): Antagonism between lysergic acid dieth- ylamide and 5-hydroxytryptamine. J Physiol (London) 121:15P
10. Grotewiel MS, Chu H, Sanders-Bush E (1994): m-chlorophe- nylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. J Pharmacol Exp Ther 271:1122-1126
11. Hoyer D, Clarke DE, Fozzard JR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994): International union of pharmacology classification of receptors for 5-hydrox- ytryptamine (serotonin). Pharmacol Rev 46:157-203
12. Kaufman MJ, Hartig PR, Hoffman BJ (1995): Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus. J Neurochem 64:199-205
13. Krebs-Thomson K, Paulus MP, Geyer MA (1998): Effects of hallucinogens on locomoter and investigatory activity and patterns: Influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 18:339-351
14. Krupnick JG, Benovic JL (1998): The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319
15. Lucaites VL, Nelson DL, Wainscott DB, Baez M (1996): Receptor subtype and density determine the coupling repertoire of the 5-HT2 receptor subfamily. Life Sci 59:1081-1095
16. Marek GJ, Aghajanian GK (1996): LSD and the phenethy- lamine hallucinogen DOI are potent agonists at 5-HT2A receptors on interneurones in rat piriform cortex. J Phar- macol Exp Ther 278:1373-1382
17. Marek GJ, Aghajanian GK (1998): Indoleamine and the phen- ethylamine hallucinogens: Mechanisms of psychotomi- metic action. Drug Alcohol Depend 51:189-198
18. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E (1999): RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences consti- tutive activity. J Biol Chem 274:9472-9478
19. Niswender CM, Sanders-Bush E, Emeson RB (1998): Identifi- cation and characterization of RNA editing events within the serotonin 5-HT2C receptor. NY Acad Sci 861:38-48
20. Pawson T, Scott JD (1997): Signaling through scaffold, anchoring, and adaptor proteins. Science 278:2075-2080
21. Sanders-Bush E, Burris KD, Knoth K (1988): Lysergic acid diethylamide and 2, 5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phos- phoinositide hydrolysis. J Pharmacol Exp Ther 246:924-928
22. Sanders-Bush E, Canton H (1995): Serotonin receptors: Signal transduction pathways. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, Ltd., pp 431-441
23. Simpson L, Emeson RB (1996): RNA editing. Annu Rev Neurosci 19:27-52
24. Titeler M, Lyon RA, Glennon RA (1988): Radioligand bind- ing evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallu- cinogens. Psychopharmacology 94:213-216
25. Wooley DL, Shaw E (1954): A biochemical and pharmacolog- ical suggestion about certain mental disorders. Proc Natl Acad Sci 40:228-231